This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by FIELD, J. B. Articles by GRIFFITH, G. C. Search for Related Content PubMed PubMed Citation Articles by FIELD, J. B. Articles by GRIFFITH, G. C.

(Circulation. 1955;11:576.)
© 1955 American Heart Association, Inc.

---

Dipaxin—2-Diphenylacetyl-1,3-Indandione; Clinical Evaluation of a New Anticoagulant

JOHN B. FIELD PH.D., M.D.¹; MARTIN S. GOLDFARB M.D.¹; ARNOLD G. WARE PH.D.¹; GEORGE C. GRIFFITH M.D.¹

¹ From the Department of Medicine, School of Medicine, University of Southern California, and the Los Angeles County General Hospital, Los Angeles, Calif.

In the course of development of new anticoagulants, an indandione derivative has been subjected to a clinical evaluation. The new agent is one of the most potent hypoprothrombinemic substance known but it is readily counteracted with vitamin K. The agent was administered to a large series of patients with thromboembolic diseases and control of anticoagulant therapy was observed to be simple, reproducible, with a good predictability of response as well as with absence of toxic phenomena and a low order of bleeding complications. It has been administered to 11 patients for ambulant anticoagulant care for periods up to 18 months with satisfactory results and it appears to be especially suitable for long-term maintenance therapy.